Enliven Therapeutics (ELVN) Form 144: Director sales total 45,000 shares

Rhea-AI Filing Summary

Enliven Therapeutics, Inc. filing under Form 144 reports proposed resale transactions involving common stock. The filing lists 45,000 shares to be sold through Jefferies LLC with an aggregate amount of $1,324,800.00 and a figure 59,000,000 on 03/09/2026. The filing also itemizes recent sales by Helen Collins: 5,000 shares for $130,878.30 and 40,000 shares for $1,046,985.20 on 02/17/2026.

Insights

Securities Compliance Counsel

Form 144 reports planned and recent resales of Enliven common shares.

The filing lists a proposed brokered resale of 45,000 common shares through Jefferies LLC with an aggregate amount of $1,324,800.00 and includes two recorded dispositions by Helen Collins on 02/17/2026.

These entries are routine resale disclosures under Rule 144; cash‑flow treatment and whether the sales are by affiliates are not specified in the excerpt. Subsequent SEC filings or broker confirmations would show execution details.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	45000	1324800.00	59000000	03/09/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/09/2022	Stock Options	Enliven Therapeutics Inc.			45000	08/09/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Helen Collins 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics, Inc.	02/17/2026	5000	130878.30
Helen Collins 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics, Inc.	02/17/2026	40000	1046985.20

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Enliven Therapeutics' Form 144 (ELVN) report?

It reports proposed and recent resales of common stock. The filing lists 45,000 shares offered through Jefferies LLC and two sales by Helen Collins totaling 45,000 shares on 02/17/2026.

Who is the broker handling the proposed resale in the Form 144?

The proposed resale is listed with Jefferies LLC as the broker. The entry shows 45,000 common shares and an aggregate amount of $1,324,800.00 in the excerpt.

What recent insider sales are disclosed for ELVN in this filing?

Helen Collins reported two sales on 02/17/2026: 5,000 shares for $130,878.30 and 40,000 shares for $1,046,985.20, as shown in the excerpt.

Does the Form 144 state how proceeds will be used by the company?

No. The excerpt does not state any use of proceeds; it lists resale quantities and amounts. The filing focuses on resale reporting rather than company receipt of proceeds.

Is the number 59,000,000 in the filing a shares outstanding figure?

The excerpt shows the number 59,000,000 alongside other securities data dated 03/09/2026. The filing text presents it in sequence but does not label it explicitly in the excerpt.